TP53 and non-Hodgkin lymphoma: Lastly, a study with the aim of determining the preliminary safety, tolerability, and pharmacokinetic profile of APR246 in combination with either Ibrutinib or Venetoclax plus rituximab therapy in NHL subjects with a mutant TP53 status, also including CLL patients (NCT04419389), is about to begin.